Philip Maclaughlin

QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors.

Joseph F Contrera, Lowell H Hall, Philip Maclaughlin, 2005, Current drug discovery technologies.

Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities.

Naomi L Kruhlak, R Daniel Benz, Edwin J Matthews, 2009, Regulatory toxicology and pharmacology : RTP.